Mutual funds are subject to market risk. Read all scheme documents carefully.
The fund is rated 3 stars. Investment selection within each asset type was a strength, while investment selection within each industry and balance between returns and downside risk provided some support but less strongly. Above-average fund size of Rs 28,542.7 crore was a minor drawback.
This fund has a good track record with Asset Selection/Timing, a ok track record with Stock Selection/Timing, a ok risk-reward ratio. It is important to note, however, that this fund has a 28542.697 AUM and a 1.61 expense ratio. Considering all these factors, we have rated this fund as 3.0 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
As of 5 Nov 2026
As of 31 Oct 2026
to generate long-term capital appreciation/income. investment predominantly in Large Cap and Mid Cap companies.
The scheme seeks to generate long term capital appreciation/income from a portfolio, predominantly invested in equity and equity related instruments.
Exit load of 1% if redeemed within 1 year
As of 30 Sep 2026
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| ICICI Bank Ltd. | 3.66% | ₹1,044.25 Cr | 79,00,836 |
| HDFC Bank Ltd. | 3.64% | ₹1,039.29 Cr | 1,46,64,794 |
| Axis Bank Ltd. | 1.95% | ₹557.83 Cr | 45,50,000 |
| Bharti Airtel Ltd. | 1.79% | ₹510.65 Cr | 29,06,378 |
| State Bank of India | 1.42% | ₹403.96 Cr | 42,10,091 |
| Gland Pharma Ltd. | 1.42% | ₹405.92 Cr | 14,00,000 |
| Reliance Industries Ltd. | 1.42% | ₹406.69 Cr | 34,26,186 |
| Prestige Estates Projects Ltd. | 1.30% | ₹370.48 Cr | 25,00,000 |
| Fortis Healthcare Ltd. | 1.28% | ₹364.47 Cr | 47,33,349 |
| Aurobindo Pharma Ltd. | 1.27% | ₹361.16 Cr | 21,60,032 |
